Search

Takeda Pharmaceutical Co Ltd ADR

Closed

SectorHealthcare

18.46 -1.23

Overview

Share price change

24h

Current

Min

18.43

Max

18.46

Key metrics

By Trading Economics

Income

138B

113B

Sales

105B

1.2T

P/E

Sector Avg

42.622

56.659

EPS

0.48

Dividend yield

3.42

Profit margin

9.279

Employees

47,029

EBITDA

180B

337B

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+135.99% upside

Dividends

By Acuity

Dividend yield

Sector Avg

3.42%

2.18%

Market Stats

By TradingEconomics

Market Cap

1.7B

57B

Previous open

19.69

Previous close

18.46

News Sentiment

By Acuity

100%

0%

324 / 339 Healthcare

Takeda Pharmaceutical Co Ltd ADR Chart

Past performance is not a reliable indicator of future results.

Related News

7 Sept 2026, 03:01 UTC

News

Bitcoin is trading lower today, despite Michael Saylor's prediction of a rise to $100,000. The asset remains above its 20-day moving average.

5 Sept 2026, 00:05 UTC

News

Illumina Inc will join the S&P 500 on September 21, 2026. Shares are advancing in after-market hours following the announcement.

5 Sept 2026, 00:05 UTC

News

Ionis Pharmaceuticals shares are lower in after-market hours following Novartis' announcement that the pelacarsen Phase 3 study did not meet its primary endpoint.

5 Sept 2026, 00:01 UTC

News

Royalty Pharma PLC shares fell in after-market hours following the failed Phase 3 trial of pelacarsen, impacting its funding agreement with Ionis.

5 Sept 2026, 00:01 UTC

Social Media
News

NIO shares are higher in after-market hours following a 69.1% revenue increase to approximately $4.74 billion and improved vehicle deliveries.

5 Sept 2026, 00:01 UTC

News

Bloom Energy Corp will join the S&P 500 on September 21, 2026, boosting investor visibility. Shares are trading higher in after-market hours.

5 Sept 2026, 00:01 UTC

News

Shares lower in after-market trading; Roth Capital targets $48.00.

5 Sept 2026, 00:00 UTC

News

Campbell's Co shares increased in after-market trading following workforce cuts and price hikes aimed at improving profitability.

5 Sept 2026, 00:00 UTC

News

DocuSign Inc reported stronger-than-expected second-quarter results but is trading lower in after-market hours, reflecting valuation concerns amid rising Treasury yields.

4 Sept 2026, 23:40 UTC

News

DocuSign Inc. reported strong second-quarter results and raised guidance, yet shares are trading lower in after-market hours amid valuation concerns and economic context.

4 Sept 2026, 23:35 UTC

News

AAP shares lower in after-market hours on analyst rating updates.

4 Sept 2026, 23:27 UTC

News

Photronics Inc shares traded lower in after-market hours amid a securities class action lawsuit alleging fraud related to its product pipeline and demand stability.

4 Sept 2026, 23:20 UTC

News

Monster Beverage appoints Matthew S. Burroughs as Chief Accounting Officer and Deputy CFO, with shares rising in after-market trading.

4 Sept 2026, 23:10 UTC

News

Northrop Grumman was awarded a $508.49 million contract for flight test support by the U.S. Department of Defense, shares trading higher in after-market hours.

4 Sept 2026, 23:05 UTC

News

Pomerantz LLP filed a class action lawsuit against Replimune Group Inc for alleged securities fraud, contributing to a decline in shares during after-market hours.

4 Sept 2026, 23:02 UTC

News

Illumina Inc will join the S&P 500 index effective September 21, 2026, following an announcement by Dow Jones Indices. Shares are trading higher after the news.

4 Sept 2026, 23:02 UTC

Social Media
News

Star Bulk Carriers announced a parallel listing on Euronext Athens and an equity offering. Shares are lower in after-market hours following the news.

4 Sept 2026, 23:02 UTC

News

Ionis Pharmaceuticals shares declined in after-market trading following Novartis' announcement of the failed pelacarsen Phase 3 study to reduce cardiovascular events.

4 Sept 2026, 23:00 UTC

News

Bloom Energy shares are higher in after-market trading following its inclusion in the S&P 500, effective September 21, 2026.

4 Sept 2026, 23:00 UTC

News

FirstEnergy shares rise in after-market trading following Potomac Edison's $52.8 million rate adjustment proposal to enhance electric system reliability in Maryland.

4 Sept 2026, 23:00 UTC

News

Campbell's Co announced a restructuring plan, cutting 13% of salaried jobs and closing two plants. Shares are trading higher in after-market hours.

4 Sept 2026, 22:51 UTC

Correlated Moves
News

Shares rose in after-market trading amid strength in oil sector.

4 Sept 2026, 20:08 UTC

News

Planet Fitness Inc. is facing a securities class action lawsuit alleging misleading statements on customer growth, contributing to a decline in its stock during Friday's session.

4 Sept 2026, 20:08 UTC

News
Correlated Moves

Marten Transport Ltd shares are higher, supported by a broader transportation sector rally and an amended credit facility increasing the letters-of-credit sublimit to $50 million.

4 Sept 2026, 20:08 UTC

News

Jefferies Financial Group's shares are higher as it maintains "buy" ratings and raises price targets for several banks, including Barclays and Lloyds.

4 Sept 2026, 20:08 UTC

News

El Pollo Loco Holdings to participate in two investor conferences this month. Shares are trading higher, reflecting positive sentiment despite earlier session pullback.

4 Sept 2026, 20:08 UTC

News

Intuitive Surgical shares declined to $365.21, marking a four-week low. Ongoing market challenges contributed to the stock's downward movement during the session.

4 Sept 2026, 20:08 UTC

News
Social Media
Macro Event

McDonald's shares hit a 52-week low amid ongoing challenges, including high menu prices like $15 for an Egg McMuffin, reflecting a broader market decline.

4 Sept 2026, 20:08 UTC

News

OrthoPediatrics Corp shares are lower amid broader market declines and selling pressure following a strong jobs report. A major shareholder's recent sale adds to negative sentiment.

4 Sept 2026, 20:08 UTC

Social Media
Macro Event
News
Correlated Moves

Intel shares are higher as demand for CPUs surges, driven by AI workloads. Despite a price target cut to $92, investor sentiment remains positive.

Peer Comparison

Price change

Takeda Pharmaceutical Co Ltd ADR Forecast

Price Target

By TipRanks

135.99% upside

12 Months Forecast

Average 43.54 USD  135.99%

High 43.54 USD

Low 43.54 USD

Based on 1 Wall Street analysts offering 12 month price targets forTakeda Pharmaceutical Co Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Takeda Pharmaceutical Co Ltd ADR

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience. The company provides its products under the Entyvio, Gattex/Revestive, Takecab/Vocinti, EOHILIA, Alofisel, Dexilant, Pantoloc/Controloc, Adynovate/Adynovi, Feiba, Recombinate, Hemofil/Immunate/Immunine, Takhzyro, Livtencity, ADZYNMA, Elaprase, Replagal, Advate, Flexbumin, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Exkivity, FRUZAQLA, Ninlaro, Velcade, Azilva-F, Lotriga, Iclusig, Leuplin/Enantone, Adcetris, vyvanse/elvanse, Trintellix, QDENGA, and Alunbrig brands. It has in-license agreement with BioMarin, Luxna Biotech, GlaxoSmithKline, Halozyme, and Kamada; collaboration with Neurocrine Biosciences, Inc., Seagen Inc., Anima Biotech, Denali Therapeutics, KSQ Therapeutics, Noile-Immune Biotech, Center for iPS Cell Research Application, Kyoto University (CiRA), and Charles River Laboratories; licensing agreement with Mirum Pharmaceuticals and Twist Bioscience, UCSD/Fortis Advisors, PeptiDream, MD Anderson Cancer Center, Teva Pharmaceutical Industries, and Xenetic Biosciences; collaboration and licensing agreement with Arrowhead Pharmaceuticals Inc., Engitix, Genevant Sciences Corporation, Sosei Heptares, Zedira/Dr. Falk Pharma, Exelixis, Inc., GlaxoSmithKline, Heidelberg Pharma, HUTCHMED, Presage Biosciences, Codexis, Inc., Ensoma, Envozyne, KM Biologics, and Selecta BioScience, and Ovid Therapeutics Inc.; and collaboration with ZEDIRA GmbH and Dr. Falk Pharma GmbH. It has research collaboration and licensing agreement with Crescendo Biologics, Code Bio, Immusoft, Poseida Therapeutics, and Selecta Biosciences. The company was founded in 1781 and is headquartered in Tokyo, Japan.
help-icon Live chat